Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort

Author: Eric P. Baron, Philippe Lucas, Joshua Eades & Olivia Hogue Published in The Journal of Headache and Pain May 2018 Abstract Background  Medicinal cannabis registries typically report pain as the most common reason for use. It would be clinically useful to identify patterns of cannabis treatment in migraine and headache, as compared to arthritis and…

A history of the Society of Cannabis Clinicians and its contributions and impact on the US medical cannabis movement

Dr. Kevin M.Takakuwa details the history of the SCC, which is the first and oldest U.S. medical organization promoting the use of medical cannabis.

Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials.

Authors: Rafael G. dos Santos, Francisco S. Guimarães, José Alexandre S. Crippa, et al
Expert Opinion on Drug Metabolism & Toxicology, 9 April 2020

Introduction: Recent trials using cannabidiol (CBD) have shown that most acute and prolonged adverse effects of CBD are mild to moderate, with rare serious adverse effects (SAEs). This review focused on analyzing SAEs of CBD and their possible relation to drug-drug interaction…

Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials.

Authors: Edward Chesney, Dominic Oliver, Alastair Green, Simina Sovi, Jack Wilson, Amir Englund, et al
Neuropsychopharmacology, 8 April 2020

Cannabidiol (CBD) is being investigated as a treatment for several medical disorders but there is uncertainty about its safety. We conducted the first systematic review and meta-analysis of the adverse effects of CBD across all medical indications. Double-blind randomized plac…

Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors

Authors: David B. Finlay, Kathleen J. Sircombe, Mhairi Nimick, Callum Jones, Michelle Glass
Frontiers in Pharmacology, 25 March 2020

The entourage effect was a proposed explanation for biological observations that endocannabinoid ligand activities can be modified by other lipids released from cells at the same time. An increasing volume of anecdotal reports and interest in the plant have provoked research i…

Labeling of Cannabidiol Products: A Public Health Perspective

Authors: Jamie Corroon, Douglas MacKay, William Dolphin
Cannabis and Cannabinoid Research, 6 March 2020

Introduction: Interest in the therapeutic use of cannabidiol (CBD) has reached a fever-pitch in recent months, as CBD-containing products appear everywhere from online retailers to grocery stores and gas stations. The widespread availability of hemp-derived CBD products is con…

Cannabis education needs assessment among Canadian physicians-in-training.

Canadian researchers found that the average training from physicians in training was 25% less than what they desired and that further training was paramount for them to engage in cannabis for therapeutic purposes (2020).

Medical students are unprepared to counsel patients about medical cannabis and want to learn more.

Authors: Abraham Benavides, Nicholas Gregorio, Puneet Gupta, Mikhail Kogan
Complementary Therapies in Medicine, January 2020

Introduction: Over-the-counter and prescribed medical cannabis products are used by patients for various conditions including psychiatric disorders, pain management, and other neurodegenerative conditions.1 Despite this growing public interest and increasing legal availability…

Indications and administration practices amongst medical cannabis healthcare providers: a cross-sectional survey.

A study published in BMC Family Practice sought to characterize the clinical practice characteristics of medical professionals who recommend cannabis.

Medical Use of Cannabis in 2019.

Authors: Kevin P. Hill
JAMA, 9 August 2019

Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the…

A National Needs Assessment of Canadian Nurse Practitioners Regarding Cannabis for Therapeutic Purposes.

Authors: Lynda G. Balneaves, Abeer Alraja, Daniel Ziemianski, Fairleth McCuaig, Mark Ware
Cannabis and Cannabinoid Research, March 2018

Introduction: In Canada, the Access to Cannabis for Medical Purposes Regulations (ACMPR) has given nurse practitioners (NPs) the power to authorize cannabis for therapeutic purposes (CTP) to eligible patients. This expansion in NPs’ scope of practice underscores the importance…

Physicians-in-training are not prepared to prescribe medical marijuana.

Authors: Anastasia B. Evanoff, Tiffany Quan, Carolyn Dufault, Michael Awad, Laura Jean Bierut
Drug and Alcohol Dependence, 1 November 2017

BACKGROUND: While medical marijuana use is legal in more than half of U.S. states, evidence is limited about the preparation of physicians-in-training to prescribe medical marijuana. We asked whether current medical school and graduate medical educational training prepare phys…